Education
About Us
Working with TipRanks
Follow Us
Tourmaline Bio (TRML)
NASDAQ:TRML
TRML Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.87 - $29.79
Previous CloseN/A
Volume43.44K
Average Volume (3M)315.83K
Market Cap
$427.66M
Enterprise Value$380.84M
Total Cash (Recent Filing)$30.51M
Total Debt (Recent Filing)$244.00K
Price to Earnings (P/E)―
Beta1.39
Next Earnings
May 19, 2025EPS Estimate
-0.9Last Dividend Ex-Date
Oct 20, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)-2.88
Shares Outstanding25,685,429
10 Day Avg. Volume404,331
30 Day Avg. Volume315,833
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.25
Forecast
1Y Price Target
$54.14Price Target Upside225.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
---
Bulls Say, Bears Say
Bulls Say
Efficacy And DosingPaci Q3M dosing can deliver similar/superior efficacy to Zilti Q1M dosing, thereby establishing a potentially best-in-class profile in IL-6 space.
Market PotentialThe involvement of IL-6 in inflammation represents an unmet need in ASCVD, providing a large market opportunity.
Safety ProfilePacibekitug trials showed no infection concerns, indicating a favorable safety profile.
Strategic OpportunitiesPhII readout is an opportunity for TRML to establish itself as a potential best-in-class player in IL-6, increasing strategic optionality.
Bears Say
Differentiation RiskIf TRML fails to demonstrate best-in-class potential compared to competitors, it could face significant market challenges.
Market CompetitionThere is a 30-50%+ downside on lack of differentiation from Zilti.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TRML FAQ
What was Tourmaline Bio’s price range in the past 12 months?
Tourmaline Bio lowest stock price was $11.87 and its highest was $29.79 in the past 12 months.
What is Tourmaline Bio’s market cap?
Tourmaline Bio’s market cap is $427.66M.
When is Tourmaline Bio’s upcoming earnings report date?
Tourmaline Bio’s upcoming earnings report date is May 19, 2025 which is in 49 days.
How were Tourmaline Bio’s earnings last quarter?
Tourmaline Bio released its earnings results on Mar 13, 2025. The company reported -$0.86 earnings per share for the quarter, missing the consensus estimate of -$0.855 by -$0.005.
Is Tourmaline Bio overvalued?
According to Wall Street analysts Tourmaline Bio’s price is currently Undervalued.
Does Tourmaline Bio pay dividends?
Tourmaline Bio pays a Notavailable dividend of $1.511 which represents an annual dividend yield of N/A. See more information on Tourmaline Bio dividends here
What is Tourmaline Bio’s EPS estimate?
Tourmaline Bio’s EPS estimate is -0.9.
How many shares outstanding does Tourmaline Bio have?
Tourmaline Bio has 25,685,429 shares outstanding.
What happened to Tourmaline Bio’s price movement after its last earnings report?
Tourmaline Bio reported an EPS of -$0.86 in its last earnings report, missing expectations of -$0.855. Following the earnings report the stock price went up 4.733%.
Which hedge fund is a major shareholder of Tourmaline Bio?
Currently, no hedge funds are holding shares in TRML
---
Tourmaline Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.14 (225.17% Upside)
$54.14 (225.17% Upside)
Hedge Fund Trend
Increased
By 23.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.29%
12-Months-Change
Fundamentals
Return on Equity
-28.99%
Trailing 12-Months
Asset Growth
46.94%
Trailing 12-Months
Company Description
Tourmaline Bio
Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.
---
TRML Stock 12 Month Forecast
Average Price Target
$54.14
▲(225.17% Upside)
Technical Analysis
Best Analysts Covering TRML
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
-0.31%
reiterated a buy rating 22 days ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of -0.31% per trade.
---